TRVN - Why Is Neurology Focused Trevena Stock Trading Higher Today? | Benzinga
Trevena Inc (NASDAQ: TRVN) released preliminary topline data from two Phase 1 proof-of-concept studies of TRV045.
Data from both studies demonstrated CNS penetration and target engagement, as well as plasma exposures in the anticipated active dose range, supporting the therapeutic potential of TRV045.
The Target Engagement POC study in 25 subjects used the validated PainCart set of analgesic tests to evaluate potential central and peripheral nervous system effects and to provide insight into the potential anti-inflammatory actions of TRV045.
TRV045 demonstrated a statistically significant, ...